AU1339795A - Non-peptide tachykinin receptor antagonists - Google Patents

Non-peptide tachykinin receptor antagonists

Info

Publication number
AU1339795A
AU1339795A AU13397/95A AU1339795A AU1339795A AU 1339795 A AU1339795 A AU 1339795A AU 13397/95 A AU13397/95 A AU 13397/95A AU 1339795 A AU1339795 A AU 1339795A AU 1339795 A AU1339795 A AU 1339795A
Authority
AU
Australia
Prior art keywords
receptor antagonists
tachykinin receptor
peptide tachykinin
peptide
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13397/95A
Inventor
Thomas Alan Crowell
Bruce Donald Gitter
Charles David Jones
William Henry Walker Lunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1339795A publication Critical patent/AU1339795A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
AU13397/95A 1993-12-21 1994-12-14 Non-peptide tachykinin receptor antagonists Abandoned AU1339795A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17113493A 1993-12-21 1993-12-21
US171134 1993-12-21
PCT/US1994/014312 WO1995017382A1 (en) 1993-12-21 1994-12-14 Non-peptide tachykinin receptor antagonists

Publications (1)

Publication Number Publication Date
AU1339795A true AU1339795A (en) 1995-07-10

Family

ID=22622667

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13397/95A Abandoned AU1339795A (en) 1993-12-21 1994-12-14 Non-peptide tachykinin receptor antagonists

Country Status (7)

Country Link
EP (1) EP0736007A4 (en)
JP (1) JPH09506898A (en)
AU (1) AU1339795A (en)
CA (1) CA2176130A1 (en)
MX (1) MXPA99001870A (en)
WO (1) WO1995017382A1 (en)
ZA (1) ZA9410040B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
AU1440395A (en) * 1993-12-21 1995-07-10 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
EP0707852A3 (en) * 1994-10-20 1998-08-19 Eli Lilly And Company Bicyclic bradykinin receptor antagonists
EP0716854A3 (en) * 1994-10-20 1996-08-28 Lilly Co Eli Compositions for inhibiting neuropeptide y receptors
EP2266560A1 (en) * 1996-03-26 2010-12-29 Eli Lilly & Company Benzothiophenes, formulations containing same, and methods
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
ES2232946T3 (en) 1997-04-30 2005-06-01 Eli Lilly And Company ANTITROMBOTIC AGENTS.
WO1998048794A1 (en) 1997-04-30 1998-11-05 Eli Lilly And Company Antithrombotic agents
CA2287982A1 (en) 1997-04-30 1998-11-05 Michael Enrico Richett Antithrombotic agents
CA2287993A1 (en) 1997-04-30 1998-11-05 Mary George Johnson Antithrombotic agents
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
EP0997460B1 (en) * 1998-10-28 2002-12-11 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
EP1401446B1 (en) 2001-05-22 2005-02-09 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
JP2004531562A (en) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー 2-Substituted 1,2,3,4-tetrahydroquinoline and its derivatives, compositions and methods
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
EP1904069B1 (en) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0616463A2 (en) 2005-09-29 2011-06-21 Merck & Co Inc compound, pharmaceutical composition, and use of a compound
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (en) 2008-03-03 2011-05-19 タイガー ファーマテック Tyrosine kinase inhibitor
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibitors of akt activity
KR20120034644A (en) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
NZ596104A (en) 2009-05-12 2014-01-31 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
KR20120023072A (en) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
BR112012008849A2 (en) 2009-10-14 2015-09-22 Schering Corp compound, pharmaceutical composition, and use of a compound
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (en) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA)
HUE044815T2 (en) 2010-08-17 2019-11-28 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
BR112015012295A8 (en) 2012-11-28 2023-03-14 Merck Sharp & Dohme USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1300575B (en) * 1965-05-21 1969-08-07 Bristol Myers Co Benzo [b] thiophenes
US3880891A (en) * 1973-09-21 1975-04-29 Smithkline Corp Substituted benzofurans
US3975537A (en) * 1973-09-21 1976-08-17 Smith Kline Pharmaceutical compositions and methods of producing coronary vasodilation
US3947470A (en) * 1974-06-20 1976-03-30 Smithkline Corporation Substituted benzofurans and benzothiophenes
US4024273A (en) * 1974-06-20 1977-05-17 Smithkline Corporation Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
EP0736007A1 (en) 1996-10-09
MXPA99001870A (en) 2004-09-06
CA2176130A1 (en) 1995-06-29
WO1995017382A1 (en) 1995-06-29
JPH09506898A (en) 1997-07-08
ZA9410040B (en) 1996-06-18
EP0736007A4 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
AU1339795A (en) Non-peptide tachykinin receptor antagonists
AU8153994A (en) Non-peptide tachykinin receptor antagonists
AU5440996A (en) 2-acylaminopropanamides as tachykinin receptor antagonists
AU1273195A (en) Tachykinin antagonists
AU1765695A (en) Non-peptidyl tachykinin receptor antagonists
AU1441695A (en) Fibrinogen receptor antagonists
AU5342894A (en) Tachykinin antagonists
AU7692996A (en) Receptor antagonists
AU4772096A (en) Delta opioid receptor antagonists
AU3665793A (en) Fibrinogen receptor antagonists
AU1842995A (en) N-acylpiperidine tachykinin antagonists
AU4343796A (en) Tachykinin antagonists
AU5873594A (en) Endothelin receptor antagonists
IL111431A0 (en) Endothelin receptor antagonists
AU4718093A (en) Substituted amines as tachykinin receptor antagonists
AU3579897A (en) Fibrinogen receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
GB9405317D0 (en) Fibrinogen receptor antagonists
AU4746297A (en) Vitronectin receptor antagonists
AU5603094A (en) N,n-diacylpiperazine tachykinin antagonists
EP0810994A4 (en) Fibrinogen receptor antagonists
AU4679793A (en) Endothelin receptor antagonists
AU4803996A (en) Endothelin receptor antagonists
EP0866705A4 (en) Fibrinogen receptor antagonists
HU9403469D0 (en) Excitatory receptor antagonists